MeadowBrook Investment Advisors LLC Acquires 289 Shares of Eli Lilly and Company $LLY

MeadowBrook Investment Advisors LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 92.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 600 shares of the company’s stock after purchasing an additional 289 shares during the period. MeadowBrook Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $468,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Lazard Freres Gestion S.A.S. lifted its stake in Eli Lilly and Company by 114.3% in the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after buying an additional 41,222 shares during the period. Precedent Wealth Partners LLC lifted its stake in Eli Lilly and Company by 15.3% in the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after buying an additional 39 shares during the period. Capital Advisors Inc. OK lifted its stake in Eli Lilly and Company by 6.8% in the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after buying an additional 429 shares during the period. Family CFO Inc acquired a new position in Eli Lilly and Company in the second quarter valued at about $54,000. Finally, Duquesne Family Office LLC lifted its stake in Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after buying an additional 32,640 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY opened at $810.78 on Thursday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a market capitalization of $767.37 billion, a PE ratio of 52.99, a P/E/G ratio of 1.22 and a beta of 0.47. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63. The stock has a 50 day simple moving average of $775.02 and a 200 day simple moving average of $770.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s quarterly revenue was up 37.6% on a year-over-year basis. During the same period last year, the company earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 39.22%.

Analyst Ratings Changes

LLY has been the topic of several analyst reports. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. HSBC boosted their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Deutsche Bank Aktiengesellschaft decreased their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Finally, UBS Group decreased their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $938.61.

Insider Buying and Selling at Eli Lilly and Company

In other news, Director J Erik Fyrwald acquired 1,565 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO David A. Ricks acquired 1,632 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 4,514 shares of company stock valued at $2,894,841 in the last 90 days. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.